Haemostatic management of extreme challenges to haemostasis in acquired von Willebrand syndrome

被引:9
作者
Colella, M. P. [1 ]
Duarte, G. C. [2 ]
Marques, J. F. C., Jr. [1 ,2 ]
De Paula, E. V. [1 ,2 ]
机构
[1] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, BR-13081878 Campinas, SP, Brazil
[2] Ctr Hematol & Hemoterapia Celular, Campinas, SP, Brazil
关键词
acquired von Willebrand syndrome; haematopoietic stem cell transplantation; multiple myeloma;
D O I
10.1111/j.1365-2516.2012.02769.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
. Acquired von Willebrand syndrome (AVWS) is a rare hemorrhagic condition for which very little information is available regarding the management of extreme challenges to Haemostasis. The AVWS is more common in the elderly, who are frequently exposed to invasive procedures and/or chemotherapy. Haematopoietic stem cell transplantation (HSCT) is a situation in which the haemostatic capacity is challenged by severe thrombocytopaenia, chemotherapy-associated mucosal barrier breakdown and the need for invasive procedures. In our report, we present and discuss the haemostatic management of a patient with AVWS who was refractory to Von Willebrand factor concentrate replacement during the course of an autologous HSCT to treat multiple myeloma. Patients with AVWS are frequently exposed to high-risk haemostatic challenges, and additional information about the haemostatic management of these situations is necessary.
引用
收藏
页码:e188 / e191
页数:4
相关论文
共 10 条
[1]   Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome [J].
Collins, P. ;
Budde, U. ;
Rand, J. H. ;
Federici, A. B. ;
Kessler, C. M. .
HAEMOPHILIA, 2008, 14 :49-55
[2]   The challenge of an ageing haemophilic population [J].
Dolan, G. .
HAEMOPHILIA, 2010, 16 :11-16
[3]   Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? [J].
Federici, A. B. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (04) :565-568
[4]  
Federici AB, 2000, THROMB HAEMOSTASIS, V84, P345
[5]   Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches [J].
Federici, AB ;
Stabile, F ;
Castaman, G ;
Canciani, MT ;
Mannucci, PM .
BLOOD, 1998, 92 (08) :2707-2711
[6]   Acquired von Willebrand syndrome: An update [J].
Franchini, Massimo ;
Lippi, Giuseppe .
AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (05) :368-375
[7]   Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease [J].
Friederich, PW ;
Wever, PC ;
Briët, E ;
Doorenbos, CJ ;
Levi, M .
AMERICAN JOURNAL OF HEMATOLOGY, 2001, 66 (04) :292-294
[8]   Clinical significance of inhibitors in acquired von Willebrand syndrome [J].
Mohri, H ;
Motomura, S ;
Kanamori, H ;
Matsuzaki, M ;
Watanabe, S ;
Maruta, A ;
Kodama, F ;
Okubo, T .
BLOOD, 1998, 91 (10) :3623-3629
[9]   Acquired von Willebrand syndrome: Features and management [J].
Mohri, Hiroshi .
AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (08) :616-623
[10]   How I treat the acquired von Willebrand syndrome [J].
Tiede, Andreas ;
Rand, Jacob H. ;
Budde, Ulrich ;
Ganser, Arnold ;
Federici, Augusto B. .
BLOOD, 2011, 117 (25) :6777-6785